NHS Trials AI Blood Test to Reduce Invasive Womb Cancer Scans

NHS trusts are pioneering an AI-powered blood test designed to streamline the diagnostic process for suspected womb cancer, offering a significantly less invasive alternative to traditional examinations. This groundbreaking technology holds the potential to spare thousands of women each year from undergoing often painful and intrusive transvaginal ultrasound scans, dramatically improving patient comfort and experience. The new diagnostic tool is being evaluated by two NHS trusts, specifically targeting postmenopausal women who present with significant bleeding – a common symptom that raises concerns for potential womb cancer. With approximately 90,000 women in England annually referred by their GPs for further investigation due to such symptoms, the current standard protocol frequently mandates an intrusive ultrasound. This pioneering AI blood test aims to accurately identify cases where such a procedure might be unnecessary, thereby streamlining the diagnostic process, reducing anxiety, and allocating resources more efficiently. By offering a less discomforting and more convenient initial screening method, the trial seeks to enhance overall patient care and diagnostic precision for a critical health concern.